| Subtype | Marker | Function, clinical relevance | Reference |
| Osteosarcoma | Sarcosphere | Drug resistance, overexpressing Oct3/4, Nanog, and Stat3 | [16ā19] | CD133 | Sphere formation, multipotency, tumorigenicity, self-renewal, inclusion of SP cells, overexpressing Oct3/4 and Nanog | [24ā26] | /CD49 | Sphere formation, migration, invasion, tumorigenicity, lung metastasis | [28] | /CD44 | Sphere formation, migration, invasion, tumorigenicity, lung metastasis | [27] | CD117/Stro-1 | Drug resistance, invasion, metastasis, tumorigenicity, self-renewal, overexpressing ABCG2 and CXCR4 | [25, 41] | SP | Drug resistance, self-renewal, tumorigenicity | [34, 35] | /CD248 | Tumorigenicity, invasion | [40] | ALDH | Proliferation, tumorigenicity, overexpressing Oct3/4, Nanog, Sox2, and Stat3 | [47, 48] | CBX3 and ABCA5 | Highly expressed in spheres | [49] | CD47 | Invasion, blockage of macrophage phagocytosis, prognostic value | [52] | CD271 | Self-renewal, differentiation, drug resistance, tumorigenicity, overexpressing Oct3/4, Nanog, Stat3, Bcl-2, and ABCG2 | [54] | Oct3/4 | Tumorigenicity, self-renewal | [57, 58] | Sox2 | Soft agar growth, migration, invasion, tumorigenicity, reduced Wnt signaling | [59] |
| Ewing sarcoma | Sarcosphere | Drug resistance, overexpressing Oc3/4, Nanog, Stat3, Sox2, Sox 10, and EWS-FLI1, fail to self-renew and enhance tumorigenicity | [19, 20] | CD133 | Sphere formation, multipotency, tumorigenicity, overexpressing Oct3/4 and Nanog, no difference in drug resistance and tumorigenicity | [29, 30] | CD57 | Migration, invasion, multipotency, tumorigenicity, no correlation with CD133 | [55] | SP | Drug resistance, clonogenicity, invasion, asymmetric division | [33, 36, 37] | ALDH | Clonogenicity, sphere formation, tumorigenicity, drug resistance | [46] |
| Chondrosarcoma | Sarcosphere | Multipotency, overexpressing Oct3/4, Nanog, and Stat3, expressing Stro-1, CD44, and CD105 | [16] | CD133 | Tumorigenicity | [25] | SP | NA | [34] |
|
|